| Literature DB >> 25249264 |
Marta Ruiz-Riol1, Anuska Llano1, Javier Ibarrondo2, Jennifer Zamarreño1, Karina Yusim3, Vanessa Bach1, Beatriz Mothe4, Susana Perez-Alvarez5, Marco A Fernandez6, Gerard Requena6, Michael Meulbroek7, Ferran Pujol7, Agathe Leon8, Patricia Cobarsi9, Bette T Korber3, Bonaventura Clotet4, Carmela Ganoza10, Jorge Sanchez10, Josep Coll11, Christian Brander12.
Abstract
The characterization of host immune responses to human immunodeficiency virus (HIV) in HIV controllers and individuals with high exposure but seronegativity to HIV (HESN) is needed to guide the development of effective preventive and therapeutic vaccine candidates. However, several technical hurdles severely limit the definition of an effective virus-specific T-cell response. By using a toggle-peptide approach, which takes HIV sequence diversity into account, and a novel, boosted cytokine staining/flow cytometry strategy, we here describe new patterns of T-cell responses to HIV that would be missed by standard assays. Importantly, this approach also allows detection of broad and strong virus-specific T-cell responses in HESN individuals that are characterized by a T-helper type 1 cytokine-like effector profile and produce cytokines that have been associated with potential control of HIV infection, including interleukin 10, interleukin 13, and interleukin 22. These results establish a novel approach to improve the current understanding of HIV-specific T-cell immunity and identify cellular immune responses and individual cytokines as potential markers of relative HIV resistance. As such, the findings also help develop similar strategies for more-comprehensive assessments of host immune responses to other human infections and immune-mediated disorders.Entities:
Keywords: HIV infection; T-cell responses; Th1 cytokines; Th17 cytokines; Th2 cytokines; boosted flow cytometry; highly exposed seronegative; toggled peptides
Mesh:
Substances:
Year: 2014 PMID: 25249264 PMCID: PMC4416125 DOI: 10.1093/infdis/jiu534
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 5.226